A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer

Kyong Joo Lee, Seung Woo Yi, Jihye Cha, Jinsil Seong, Seungmin Bang, Si Young Song, Heeman Kim, Seung Woo Park

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Combination chemotherapy with gemcitabine and cisplatin is a standard treatment for patients with advanced biliary tract cancer. This study aimed to evaluate the efficacy and safety of gemcitabine- and cisplatin-based concurrent chemoradiotherapy in patients with unresectable biliary tract cancer. Methods: Patients with pathologically proven, unresectable, non-metastatic biliary tract cancer were enrolled. Gemcitabine was administered intravenously at a dose of 1000 mg/m2 on days 1, 8, and 15. Cisplatin was administered intravenously at a dose of 70 mg/m2 on day 1. All the patients underwent concurrent radiotherapy with 45 Gy in 1.8-Gy daily fractions. After treatment completion, tumor response was evaluated by using computed tomography. Results: Eighteen patients were enrolled between June 2007 and October 2011. Their median age was 61 years (range, 38–72 years). Eight patients (44.5 %) were diagnosed with gallbladder cancer, six (33.3 %) with Klatskin’s tumor, and four (22.2 %) with distal common bile duct cancer. After treatment completion, partial response was achieved in five patients (27.8 %) and stable disease in 13 patients (72.2 %). The overall response rate was 27.8 %, and the disease stabilization rate was 100 %. No grade 4 adverse events or treatment-related deaths occurred. The most common grade 3 adverse events were thrombocytopenia (33.3 %) and anemia (11.1 %). The median progression-free and overall survival times were 6.8 months (range, 4.5–19.8 months) and 9.6 months (5.4–30.4 months), respectively. Conclusions: This study shows that gemcitabine- and cisplatin-based concurrent chemoradiotherapy is feasible and tolerable in patients with unresectable and non-metastatic biliary tract cancer.

Original languageEnglish
Pages (from-to)841-846
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume78
Issue number4
DOIs
Publication statusPublished - 2016 Oct 1

Fingerprint

gemcitabine
Chemoradiotherapy
Biliary Tract Neoplasms
Cisplatin
Tumors
Chemotherapy
Radiotherapy
Ducts
Tomography
Stabilization
Klatskin Tumor
Bile Duct Neoplasms
Gallbladder Neoplasms
Common Bile Duct
Therapeutics
Combination Drug Therapy
Thrombocytopenia

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Lee, Kyong Joo ; Yi, Seung Woo ; Cha, Jihye ; Seong, Jinsil ; Bang, Seungmin ; Song, Si Young ; Kim, Heeman ; Park, Seung Woo. / A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. In: Cancer Chemotherapy and Pharmacology. 2016 ; Vol. 78, No. 4. pp. 841-846.
@article{e2719eafc9a645cfaa887bad0ad66273,
title = "A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer",
abstract = "Purpose: Combination chemotherapy with gemcitabine and cisplatin is a standard treatment for patients with advanced biliary tract cancer. This study aimed to evaluate the efficacy and safety of gemcitabine- and cisplatin-based concurrent chemoradiotherapy in patients with unresectable biliary tract cancer. Methods: Patients with pathologically proven, unresectable, non-metastatic biliary tract cancer were enrolled. Gemcitabine was administered intravenously at a dose of 1000 mg/m2 on days 1, 8, and 15. Cisplatin was administered intravenously at a dose of 70 mg/m2 on day 1. All the patients underwent concurrent radiotherapy with 45 Gy in 1.8-Gy daily fractions. After treatment completion, tumor response was evaluated by using computed tomography. Results: Eighteen patients were enrolled between June 2007 and October 2011. Their median age was 61 years (range, 38–72 years). Eight patients (44.5 {\%}) were diagnosed with gallbladder cancer, six (33.3 {\%}) with Klatskin’s tumor, and four (22.2 {\%}) with distal common bile duct cancer. After treatment completion, partial response was achieved in five patients (27.8 {\%}) and stable disease in 13 patients (72.2 {\%}). The overall response rate was 27.8 {\%}, and the disease stabilization rate was 100 {\%}. No grade 4 adverse events or treatment-related deaths occurred. The most common grade 3 adverse events were thrombocytopenia (33.3 {\%}) and anemia (11.1 {\%}). The median progression-free and overall survival times were 6.8 months (range, 4.5–19.8 months) and 9.6 months (5.4–30.4 months), respectively. Conclusions: This study shows that gemcitabine- and cisplatin-based concurrent chemoradiotherapy is feasible and tolerable in patients with unresectable and non-metastatic biliary tract cancer.",
author = "Lee, {Kyong Joo} and Yi, {Seung Woo} and Jihye Cha and Jinsil Seong and Seungmin Bang and Song, {Si Young} and Heeman Kim and Park, {Seung Woo}",
year = "2016",
month = "10",
day = "1",
doi = "10.1007/s00280-016-3143-2",
language = "English",
volume = "78",
pages = "841--846",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. / Lee, Kyong Joo; Yi, Seung Woo; Cha, Jihye; Seong, Jinsil; Bang, Seungmin; Song, Si Young; Kim, Heeman; Park, Seung Woo.

In: Cancer Chemotherapy and Pharmacology, Vol. 78, No. 4, 01.10.2016, p. 841-846.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer

AU - Lee, Kyong Joo

AU - Yi, Seung Woo

AU - Cha, Jihye

AU - Seong, Jinsil

AU - Bang, Seungmin

AU - Song, Si Young

AU - Kim, Heeman

AU - Park, Seung Woo

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Purpose: Combination chemotherapy with gemcitabine and cisplatin is a standard treatment for patients with advanced biliary tract cancer. This study aimed to evaluate the efficacy and safety of gemcitabine- and cisplatin-based concurrent chemoradiotherapy in patients with unresectable biliary tract cancer. Methods: Patients with pathologically proven, unresectable, non-metastatic biliary tract cancer were enrolled. Gemcitabine was administered intravenously at a dose of 1000 mg/m2 on days 1, 8, and 15. Cisplatin was administered intravenously at a dose of 70 mg/m2 on day 1. All the patients underwent concurrent radiotherapy with 45 Gy in 1.8-Gy daily fractions. After treatment completion, tumor response was evaluated by using computed tomography. Results: Eighteen patients were enrolled between June 2007 and October 2011. Their median age was 61 years (range, 38–72 years). Eight patients (44.5 %) were diagnosed with gallbladder cancer, six (33.3 %) with Klatskin’s tumor, and four (22.2 %) with distal common bile duct cancer. After treatment completion, partial response was achieved in five patients (27.8 %) and stable disease in 13 patients (72.2 %). The overall response rate was 27.8 %, and the disease stabilization rate was 100 %. No grade 4 adverse events or treatment-related deaths occurred. The most common grade 3 adverse events were thrombocytopenia (33.3 %) and anemia (11.1 %). The median progression-free and overall survival times were 6.8 months (range, 4.5–19.8 months) and 9.6 months (5.4–30.4 months), respectively. Conclusions: This study shows that gemcitabine- and cisplatin-based concurrent chemoradiotherapy is feasible and tolerable in patients with unresectable and non-metastatic biliary tract cancer.

AB - Purpose: Combination chemotherapy with gemcitabine and cisplatin is a standard treatment for patients with advanced biliary tract cancer. This study aimed to evaluate the efficacy and safety of gemcitabine- and cisplatin-based concurrent chemoradiotherapy in patients with unresectable biliary tract cancer. Methods: Patients with pathologically proven, unresectable, non-metastatic biliary tract cancer were enrolled. Gemcitabine was administered intravenously at a dose of 1000 mg/m2 on days 1, 8, and 15. Cisplatin was administered intravenously at a dose of 70 mg/m2 on day 1. All the patients underwent concurrent radiotherapy with 45 Gy in 1.8-Gy daily fractions. After treatment completion, tumor response was evaluated by using computed tomography. Results: Eighteen patients were enrolled between June 2007 and October 2011. Their median age was 61 years (range, 38–72 years). Eight patients (44.5 %) were diagnosed with gallbladder cancer, six (33.3 %) with Klatskin’s tumor, and four (22.2 %) with distal common bile duct cancer. After treatment completion, partial response was achieved in five patients (27.8 %) and stable disease in 13 patients (72.2 %). The overall response rate was 27.8 %, and the disease stabilization rate was 100 %. No grade 4 adverse events or treatment-related deaths occurred. The most common grade 3 adverse events were thrombocytopenia (33.3 %) and anemia (11.1 %). The median progression-free and overall survival times were 6.8 months (range, 4.5–19.8 months) and 9.6 months (5.4–30.4 months), respectively. Conclusions: This study shows that gemcitabine- and cisplatin-based concurrent chemoradiotherapy is feasible and tolerable in patients with unresectable and non-metastatic biliary tract cancer.

UR - http://www.scopus.com/inward/record.url?scp=84984815379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984815379&partnerID=8YFLogxK

U2 - 10.1007/s00280-016-3143-2

DO - 10.1007/s00280-016-3143-2

M3 - Article

C2 - 27586966

AN - SCOPUS:84984815379

VL - 78

SP - 841

EP - 846

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -